Tryptamine Therapeutics Limited (ASX:TYP) is a clinical-stage biotech and its current primary focus is the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs. The Company’s Phase 2a clinical trial investigating the treatment of Irritable Bowel Syndrome (‘IBS’) is now underway and recently dosed the first patient at Massachusetts General Hospital – the first time this prestigious US hospital has administered psilocybin in a clinical setting. Tryptamine Therapeutics CEO and Executive Director Jason Carroll speaks with The Stock Network’s Lel Smits.
1 TRP-8803 (IVinfused psilocin formulation)
Tryptamine Therapeutics is now focusing on the creation of defined clinical trial pathways for its two core programs, one of which is TRP-8803. What does this IV-infused psilocin formulation entail?
2 Treatment advantages of TRP-8803
What potential advantages does TRP-8803 offer from a treatment perspective?
3 TRP-8802 (oral psilocybin)
Your second clinical program is the oral psilocybin TRP-8802. A Phase 2A clinical trial of TRP-8802, undertaken in collaboration with the University of Michigan, has just completed. What do you expect to come out of this trial?
_ _ _
Subscribe to TSN’s YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _
Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/
_ _ _
Connect with our host Lel Smits online – @LelSmits
– Twitter / X: https://twitter.com/lelsmits
– Instagram: https://www.instagram.com/lelsmits/
– LinkedIn: https://www.linkedin.com/in/leldesmits/
– TikTok: https://www.tiktok.com/@lelsmits?lang=en
– Facebook: https://m.facebook.com/lelsmits/
– Threads: https://www.threads.net/@lelsmits
_ _ _
Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.
This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.
_ _ _
Visit TSN’s website to sign up for regular stock updates: http://www.thestocknetwork.com.au
_ _ _